News | Radiology Imaging | January 22, 2020

Groups Publish Statements on CT Contrast Use in Patients with Kidney Disease

Iodine-based CT contrast ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs.

January 22, 2020 — The risk of administering modern intravenous iodinated contrast media in patients with reduced kidney function has been overstated, according to new consensus statements from the American College of Radiology (ACR) and the National Kidney Foundation (NKF), published in the journal Radiology.

Intravenous iodinated contrast media are commonly used with computed tomography (CT) to evaluate disease and to determine treatment response. Although patients have benefited from their use, iodinated contrast media have been denied or delayed in patients with reduced kidney function due to the perceived risks of contrast-induced acute kidney injury. This practice can hinder a timely and accurate diagnosis in these patients.

"The historical fears of kidney injury from contrast-enhanced CT have led to unmeasured harms related to diagnostic error and diagnostic delay," said lead author Matthew S. Davenport, M.D., associate professor of radiology and urology at the University of Michigan in Ann Arbor, Mich. "Modern data clarify that this perceived risk has been overstated. Our intent is to provide multi-disciplinary guidance regarding the true risk to patients and how to apply a consideration of that risk to modern clinical practice."

These consensus statements were developed to improve and standardize the care of patients with impaired kidney function who may need to undergo exams that require intravenous iodinated contrast media to provide the clearest images and allow for the most informed diagnosis.

In clinical practice, many factors are used to determine whether intravenous contrast media should be administered. These include probability of an accurate diagnosis, alternative methods of diagnosis, risks of misdiagnosis, expectations about kidney function recovery, and risk of allergic reaction. Decisions are rarely based on a single consideration, such as risk of an adverse event specifically related to kidney impairment. Consequently, the authors advise that these statements be considered in the context of the entire clinical scenario.

Importantly, the report outlines the key differences between contrast-induced acute kidney injury (CI-AKI) and contrast-associated acute kidney injury (CA-AKI). In CI-AKI, a causal relationship exists between contrast media and kidney injury, whereas in CA-AKI, a direct causal relationship has not been demonstrated. The authors suggest that studies that have not properly distinguished the two have contributed to the overstatement of risk.

"A primary explanation for the exaggerated perceived nephrotoxic risk of contrast-enhanced CT is nomenclature," Davenport said. "'Contrast-induced' acute kidney injury implies a causal relationship. However, in many circumstances, the diagnosis of CI-AKI in clinical care and in research is made in a way that prevents causal attribution. Disentangling contrast-induced AKI (causal AKI) from contrast-associated AKI (correlated AKI) is a critical step forward in improving understanding of the true risk to patients."

The statements answer key questions and provide recommendations for use of intravenous contrast media in treating patients with varying degrees of impaired kidney function.

Although the true risk of CI-AKI remains unknown, the authors recommend intravenous normal saline for patients without contraindication, such as heart failure, who have acute kidney injury or an estimated glomerular filtration rate (eGFR) less than 30 mL/min per 1.73 m2 who are not undergoing maintenance dialysis. In individual and unusual high-risk circumstances (patients with multiple comorbid risk factors), prophylaxis may be considered in patients with an eGFR of 30-44 mL/min per 1.73 m2 at the discretion of the ordering clinician.

The presence of a solitary kidney should not independently influence decision making regarding the risk of CI-AKI. Lowering of contrast media dose below a known diagnostic threshold should be avoided due to the risk of lowering diagnostic accuracy. Also, when feasible, medications that are toxic to the kidneys should be withheld by the referring clinician in patients at high risk. However, renal replacement therapy should not be initiated or altered solely based on contrast media administration.

The authors emphasize that prospective controlled data are needed in adult and pediatric populations to clarify the risk of CI-AKI.

For more information: www.rsna.org

Related Content of MRI Gadolinium Safety Concerns

Voluntary Dismissal of Chuck Norris Gadolinium Case Involving Bracco

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

Recent Developments in Contrast Media

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

European Medicines Agency Issues Update on Gadolinium Contrast Agents

 

Related Content

Steinberg Diagnostic Medical Imaging headquarters.

Steinberg Diagnostic Medical Imaging headquarters.

Sponsored Content | Case Study | Contrast Media Injectors | January 21, 2021
Steinberg Diagnostic Medical Imaging (SDMI) was founded 30 years a
For years telehealth has danced at the edges of healthcare
Feature | Teleradiology | January 21, 2021 | By Jef Williams
All indications point to 2021 being the year of the return path of this boomerang event that sent us all in a differe
The key trends Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Imagesbserved at 2020 Radiological Society of North America (RSNA) meeting all focused around COVID-19 (SARS-CoV-2) and the impact it has had on radiology. #RSNA #RSNA20 #RSNA2020

Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Images

Feature | RSNA | January 20, 2021 | By Melinda Taschetta-Millane and Dave Fornell
Radiologists have recently taken on the role of activists and are tackling pressing issues in healthcare, including breast density

Getty Images

Feature | Women's Health | January 20, 2021 | By Fazila Seker, Ph.D.
Radiologists — who have long been professionals in the metaphorical and literal back-rooms of healthcare — have recen
MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
An interview with Eric Liederman, M.D., MPH, Director of Medical Informatics for The Permanente Medical Group, in Kaiser Permanente’s Northern California Region, on the explosion of telemedicine in the COVID-19 era

Getty Images

Feature | Radiology Business | January 20, 2021 | By Melinda Taschetta-Millane
Vendor neutral archives enable a single, central location to store large volumes of radiology data, but now need to be able to house data from dozens of other departments with a wide array of data formats. This article originally ran as an introduction to the Vendor Neutral Archives comparison chart.
Feature | Vendor Neutral Archive (VNA) | January 20, 2021 | By Dave Fornell
Most radiologists and clinicians are not trained as...
According to a new research report1 on the contrast media injectors published by MarketsandMarkets, the market was estimated to be $1.3 billion in 2020 and projected to reach $1.9 billion by 2025, at a compound annual growth rate (CAGR) of 7.4 percent over 2020-2025.

The ulrich CTmotion

Feature | Contrast Media Injectors | January 20, 2021 | By Melinda Taschetta-Millane
According to a new...
Previously approved by FDA in the USA, MyLab X8 expands the reach of the MyLab Ultrasound Product Line with a fully featured premium imaging solution, integrating the latest technologies and delivering superior image quality without compromising workflow or efficiency.
News | Ultrasound Imaging | January 20, 2021
January 20, 2021 — Esaote North America announces that the...